Bixeps Machine Shows Promise in Improving Muscle Strength and Bone Density in Clinical Studies
核心洞察
A clinical study in Hong Kong validates the efficacy of Singapore's Bixeps (搜索) machine in enhancing muscle strength among patients.
Beyond muscle strengthening, patients using the Bixeps (搜索) machine have demonstrated increased bone density due to myokines generated by mitochondria stimulation.
Clinical trials are underway to assess Bixeps (搜索)' potential in reducing inflammation and slowing cancer progression in breast cancer (搜索) and leukemia (搜索) patients.
A clinical study conducted in Hong Kong has confirmed that the Bixeps (搜索) machine, developed in Singapore, effectively improves muscle strength. The machine, already in use by over 100 patients according to one physician, is now being explored for its broader health benefits, including increased bone density and potential anti-inflammatory effects in cancer patients.
Enhanced Muscle Strength and Bone Density
Professor Tay, a researcher involved in the studies, noted that patients have experienced not only muscle strengthening but also higher bone density. This is attributed to the myokines generated by the mitochondria stimulation, which are distributed throughout the body. One patient, Mrs. Louisa Chen, 82, reported improved mobility after using the machine, highlighting its potential to enhance the quality of life for elderly individuals.
Clinical Trials for Cancer Patients
Researchers at the National University of Singapore (NUS) have initiated two clinical trials to investigate the effects of Bixeps (搜索) on patients with breast cancer (搜索) and leukemia (搜索). These trials aim to determine if the machine can reduce inflammation associated with these diseases and potentially slow cancer progression. Preliminary results from these trials are reportedly promising.
Regulatory Approval and Future Availability
QuantumTX (搜索), the company behind Bixeps (搜索), has applied to both the Health Sciences Authority (HSA) in Singapore and the US Food and Drug Administration (FDA) for approval of its next-generation machine. This advanced version allows healthcare professionals to adjust the signal strength to suit the frailty levels of individual patients. Currently, the existing Bixeps machine is marketed as a wellness device and does not require regulatory approval. Once HSA approval is granted, Professor Tay intends to advocate for the acquisition of multiple Bixeps machines at his hospital to benefit patients undergoing physiotherapy. The recommended treatment duration is 10 minutes, up to three times a week, to optimize mitochondrial stimulation without weakening.